Novartis Home

The Novartis Compound Library provides automated storage for experiments.

At Novartis, we are reimagining medicine

Navigate Novartis

Members of the Executive Committee of Novartis discussing the Novartis 2018 financial results.

Leadership message

Members of our Executive Team reflect on a remarkable 2018 for the company and what to look forward to in 2019.

People walking in front of a building on the Novartis Campus, Basel in Switzerland.

Novartis 2018 Financial Results

Novartis CEO Vas Narasimhan announced the company’s fourth quarter and 2018 full year results.

Novartis Annual Reporting Suite

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.

Novartis receives FDA approval for Egaten® for the treatment of fascioliasis, a neglected tropical disease
Novartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018
Novartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease
Sandoz and Pear Therapeutics Announce US Launch of reSET-OTM to Help Treat Opioid Use Disorder